Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified-release calcium formate in adults with homocystinuria
ACTRN12625000151437Phase 2Not yet recruiting
- Sponsor
- SubRed Therapeutics
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of calcium formate in homocystinuria (HCU), sponsored by SubRed Therapeutics. Primary endpoint: Change in plasma homocysteine levels. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
calcium formate
03
Conditions
homocystinuria (HCU)
Beyond the preview
Go deeper on ACTRN12625000151437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000151437.